🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

Showing page 109 of 857 · Phase 3 first, then by program name

  1. Matching Placebo for TAK-279, ZASOCITINIB

    Takeda

    Plaque Psoriasis

    phase 3 small molecule active

    1 trial

  2. Matching Placebo for Upadacitinib

    AbbVie

    Crohn's Disease

    phase 3 small molecule completed

    1 trial

  3. Matching placebo MGL-3196 60 mg film-coated tablet, Matching placebo MGL-3196 80 mg film-coated tablet, Matching placebo MGL-3196 100 mg film-coated tablet., MGL-3196 60 mg oral, MGL-3196 100 mg oral, MGL-3196 80 mg oral

    Madrigal Pharmaceuticals EU Limited

    Non-Alcoholic Steatohepatitis (NASH)

    phase 3 small molecule active

    1 trial

  4. Matching placebo for BAY 597939 2.5 mg filmcoated tablets, Rivaroxaban 2.5 mg

    The George Institute

    Improvement of cardiovascular outcomes in patients with advanced chronic kidney disease. In easily understood language, this is Heart and blood vessel disease and Kidney disease.

    phase 3 small molecule active

    1 trial

  5. Matching placebo for Tezepelumab solution for injection, TEZEPELUMAB

    AstraZeneca AB

    Severe Uncontrolled Asthma Asthma (an illness that causes breathing difficulty) that is not fully controlled, so that asthma attacks are still occurring despite the use of other available treatments

    phase 3 small molecule active

    1 trial

  6. Matching placebo tablet, JNJ-67953964

    Janssen-Cilag International N.V.

    Major Depressive Disorder (MDD) with Moderate-to-severe Anhedonia

    phase 3 small molecule active

    1 trial

  7. Matching placebo tablet, JNJ-67953964

    Janssen-Cilag International N.V.

    Major Depressive Disorder (MDD) with Moderate-to-severe Anhedonia

    phase 3 small molecule active

    1 trial

  8. Mavorixafor

    X4 Pharmaceuticals, Inc

    WHIM Syndrome

    phase 3 small molecule active

    1 trial

  9. Mavorixafor

    X4 Pharmaceuticals, Inc

    Neutropenia

    phase 3 small molecule active

    2 trials

  10. Mavorixafor, Mavorixafor Placebo Capsules

    X4 Pharmaceuticals, Inc

    Neutropenias

    phase 3 small molecule active

    1 trial

  11. Mavorixafor, Placebo to Test IMP

    X4 Pharmaceuticals, Inc

    WHIM Syndrome

    phase 3 small molecule active

    1 trial

  12. Medi-546

    AstraZeneca

    Systemic Lupus Erythematosus

    phase 3 small molecule active

    1 trial

  13. Medical Air, KALINOX 50%/50%, gaz médicinal comprimé

    Tour Hekla

    Resistant Depression in the Elderly Subject

    phase 3 small molecule active

    1 trial

  14. Medium-dosage COVID-19 Vaccine,Inactivated

    Sinovac Research and Development Co.,

    COVID-19

    phase 3 mab terminated

    1 trial

  15. Medpulser Electroporation with Bleomycin

    INOVIO PHARMACEUTICALS, INC.

    Head Neck Cancer

    phase 3 other terminated

    1 trial

  16. Medtronic Talent Stent-Graft-System

    Rhythm Pharmaceuticals Netherlands B.V.

    Aortic Diseases

    phase 3 other completed

    1 trial

  17. Megestrol（Yining）

    The First People's Hospital of Lianyungang

    Stage III Esophageal Squamous Cell Carcinoma

    phase 3 small molecule completed

    1 trial

  18. Melflufen

    Oncopeptides AB (publ)

    Multiple Myeloma

    phase 3 small molecule terminated

    1 trial

  19. MenACWY-TT

    Pfizer

    Meningococcal ACWY Disease

    phase 3 mab completed

    1 trial

  20. MenQuadfi solution for injection Meningococcal Group A, C, W and Y conjugate vaccine

    Sanofi Pasteur

    Meningococcal infection

    phase 3 small molecule active

    1 trial

  21. Mencevax ACWY

    GlaxoSmithKline

    Infections, Meningococcal

    phase 3 mab completed

    1 trial

  22. Meningococcal Polysaccharide (Serogroups A, C, W, and Y) Tetanus Toxoid Conjugate Vaccine

    Sanofi Pasteur

    Meningococcal Infection

    phase 3 mab completed

    1 trial

  23. Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid conjugate vaccine

    Sanofi Pasteur

    Meningococcal Immunization

    phase 3 mab completed

    1 trial

  24. Meningococcal vaccine GSK134612

    GlaxoSmithKline

    Infections, Meningococcal

    phase 3 mab completed

    2 trials

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources